Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779068 | 0.88 | MAP2K1 (0.50) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL1777731 | 0.82 | CAMKK2 (0.56) | ALDH1A1MEN1KMT2ARIPK1MAPK1 | |
| SCHEMBL8321698 | 0.81 | AURKA (0.44) | MAPTRIPK1MAP2K1CCNB2CDK1 | |
| SCHEMBL1777550 | 0.76 | MAPK13 (0.48) | ALDH1A1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL21149383 | 0.74 | PDCD1 (0.67) | PDCD1CD274ALDH1A1MAPTGRM1 | |
| SCHEMBL1777876 | 0.74 | CYP11B1 (0.55) | ALDH1A1NPC1SMN1; SMN2CCNB2CDK1 | |
| SCHEMBL1778294 | 0.74 | CCNB2 (0.65) | ALDH1A1RIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL1778974 | 0.74 | MAPK13 (0.46) | ALDH1A1MAPTNPC1CCNB2CDK1 | |
| SCHEMBL25954216 | 0.69 | PDCD1 (0.85) | PDCD1CD274ALDH1A1MAPTGRM1 | |
| SCHEMBL7965829 | 0.68 | MAP2K1 (0.54) | ALDH1A1MAPTMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | claimed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | claimed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | claimed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | claimed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | claimed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | claimed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | claimed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | claimed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7227020-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| EP-0509974-B1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | ASTRA AB (SE) | 1999-01-13 | — | — | EP | disclosed |
| US-5439917-A | Phenyl-pyrrolo(2,3-b)pyridine antisecretory agent of gastric acid; adenosine triphosphatase enzyme inhibitor | AKTIEBOLAGET ASTRA (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0580616-A1 | NEW ACTIVE COMPOUNDS | Astra Aktiebolag (SE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0509974-A1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | Astra Aktiebolag (SE) | 1992-10-21 | — | — | EP | disclosed |
| WO-1992017477-A1 | NEW ACTIVE COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | PDCD1 4222/4885CD274 4503/4885ALDH1A1 4397/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | PDCD1 2840/4885CD274 3967/4885ALDH1A1 939/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | PDCD1 4068/4885CD274 4260/4885ALDH1A1 4673/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | PDCD1 1157/4885CD274 1799/4885ALDH1A1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.